Recombinant adeno-associated viral vectors in the nervous system

Human Gene Therapy

Volumn 16, Issue 7, 2005, Pages 781-791

  Burger, Corinna ^a   Nash, Kevin ^a   Mandel, Ronald J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; ASPARTOACYLASE; BETA ACTIN; BETA GALACTOSIDASE; BRAIN DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GREEN FLUORESCENT PROTEIN; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; LEVODOPA; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; PARVOVIRUS VECTOR; PLATELET DERIVED GROWTH FACTOR B; TYROSINE 3 MONOOXYGENASE;

BRAIN ATROPHY; BRAIN DISEASE; BRAIN SPONGIOSIS; CANAVAN DISEASE; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; IMMUNE RESPONSE; LEUKODYSTROPHY; LONG TERMINAL REPEAT; LYSOSOME STORAGE DISEASE; MUCOPOLYSACCHARIDOSIS TYPE 7; NEUROLOGIC DISEASE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; REVIEW; SEROTYPE; SPINAL CORD DISEASE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT;

ANIMALS; CENTRAL NERVOUS SYSTEM; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; MANNITOL; NERVOUS SYSTEM DISEASES; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS 2;

EID: 22144477188     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.781     Document Type: Review

References (135)

1. AHMED, B.Y., CHAKRAVARTHY, S., EGGERS, R., HERMENS, W.T., ZHANG, J.Y., NICLOU, S.P., LEVELT, C., SABLITZKY, F., ANDERSON, P.N., LIEBERMAN, A.R., and VERHAAGEN, J. (2004). Efficient delivery of Cre-recombinase to neurons in vivo and stable transduction of neurons using adeno-associated and lentiviral vectors. BMC Neurosci. 5, 4.
2. ALI, R.R., REICHEL, M.B., THRASHER, A.J., LEVINSKY, R.J., KINNON, C., KANUGA, N., HUNT, D.M., and BHATTACHARYA, S.S. (1996). Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum. Mol. Genet. 5, 591-594.
3. ALISKY, J.M., HUGHES, S.M., SAUTER, S.L., JOLLY, D., DUBENSKY, T.W., Jr., STABER, P.D., CHIORINI, J.A., and DAVIDSON, B.L. (2000). Transduction of murine cerebellar neurons with recombinant FIV and AAV5 vectors. Neuroreport 11, 2669-2673.
4. AURICCHIO, A., KOBINGER, G., ANAND, V., HILDINGER, M., O'CONNOR, E., MAGUIRE, A.M., WILSON, J.M., and BENNETT, J. (2001). Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: The retina as a model. Hum. Mol. Genet. 10, 3075-3081.
5. AURICCHIO, A., GAO, G.P., YU, Q.C., RAPER, S., RIVERA, V.M., CLACKSON, T., and WILSON, J.M. (2002a). Constitutive and regulated expression of processed insulin following in vivo hepatic gene transfer. Gene Ther. 9, 963-971.
6. AURICCHIO, A., RIVERA, V.M., CLACKSON, T., O'CONNOR, E.E., MAGUIRE, A.M., TOLENTINO, M.J., BENNETT, J., and WILSON, J.M. (2002b). Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye. Mol. Ther. 6, 238-242.
7. BARTLETT, J.S., SAMULSKI, R.J., and MCCOWN, T.J. (1998). Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum. Gene Ther. 9, 1181-1186.
8. BJORKLUND, A., KIRIK, D., ROSENBLAD, C., GEORGIEVSKA, B., LUNDBERG, C., and MANDEL, R.J. (2000). Towards a neuroprotective gene therapy for Parkinson's disease: Use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res. 886, 82-98.
9. BLOUIN, V., BRUMENT, N., TOUBLANC, E., RAIMBAUD, I., MOULLIER, P., and SALVETTI, A. (2004). Improving rAAV production and purification: Towards the definition of a scaleable process. J. Gene Med. 6(Suppl. 1), S223-S228.
10. BOHL, D., SALVETTI, A., MOULLIER, P., and HEARD, J.M. (1998). Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 92, 1512-1517.
11. BOSCH, A., PERRET, E., DESMARIS, N., and HEARD, J.M. (2000). Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol. Ther. 1, 63-70.
12. BURGER, C., GORBATYUK, O.S., VELARDO, M.J., PEDEN, C.S., WILLIAMS, P., ZOLOTUKHIN, S., REIER, P.J., MANDEL, R.J., and MUZYCZKA, N. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol. Ther. 10, 302-317.
13. BURGER, C., NGUYEN, F.N., DENG, J., and MANDEL, R.J. (2005). Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. Mol. Ther. 11, 327-331.
14. CARLSSON, T., WINKLER, C., BURGER, C., MUZYCZKA, N., MANDEL, R.J., CENCI, A., BJORKLUND, A., and KIRIK, D. (2005). Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain 128, 559-569.
15. CARTER, B.J. (2004). Adeno-associated virus and the development of adeno-associated virus vectors: A historical perspective. Mol. Ther. 10, 981-989.
16. CHEN, H., MCCARTY, D.M., BRUCE, A.T., and SUZUKI, K. (1999). Oligodendrocyte-specific gene expression in mouse brain: Use of a myelin-forming cell type-specific promoter in an adeno-associated virus. J. Neurosci. Res. 55, 504-513.
17. CHENUAUD, P., LARCHER, T., RABINOWITZ, J.E., PROVOST, N., JOUSSEMET, B., BUJARD, H., SAMULSKI, R.J., FAVRE, D., and MOULLIER, P. (2004). Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle. Mol. Ther. 9, 410-418.
18. CHTARTO, A., BENDER, H.U., HANEMANN, C.O., KEMP, T., LEHTONEN, E., LEVIVIER, M., BROTCHI, J., VELU, T., and TENENBAUM, L. (2003). Tetracycline-inducible transgene expression mediated by a single AAV vector. Gene Ther. 10, 84-94.
19. CUCCHIARINI, M., REN, X.L., PERIDES, G., and TERWILLIGER, E.F. (2003). Selective gene expression in brain microglia mediated via adeno-associated virus type 2 and type 5 vectors. Gene Ther. 10, 657-667.
20. DASS, B., IRAVANI, M.M., HUANG, C., BARSOUM, J., ENGBER, T.M., GALDES, A., and JENNER, P. (2004). Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat. J. Neural Transm. (Dec. 10; epub ahead of print).
21. DAVIDOFF, A.M., NG, C.Y., SLEEP, S., GRAY, J., AZAM, S., ZHAO, Y., MCINTOSH, J.H., KARIMIPOOR, M., and NATHWANI, A.C. (2004). Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods 121, 209-215.
22. DAVIDSON, B.L., STEIN, C.S., HETH, J.A., MARTINS, I., KOTIN, R.M., DERKSEN, T.A., ZABNER, J., GHODSI, A., and CHIORINI, J.A. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U.S.A. 97, 3428-3432.
23. DESMARIS, N., VEROT, L., PUECH, J.P., CAILLAUD, C., VANIER, M.T., and HEARD, J.M. (2004). Prevention of neuropathology in the mouse model of Hurler syndrome. Ann. Neurol. 56, 68-76.
24. DI PASQUALE, G., DAVIDSON, B.L., STEIN, C.S., MARTINS, I., SCUDIERO, D., MONKS, A., and CHIORINI, J.A. (2003). Identification of PDGFR as a receptor for AAV-5 transduction. Nat. Med. 9, 1306-1312.
25. DONELLO, J.E., LOEB, J.E., and HOPE, T.J. (1998). Woodchuck hepatitis virus contains a tripartite posttranscriptional regulatory element. J. Virol. 72, 5085-5092.
26. EHRENGRUBER, M.U., HENNOU, S., BUELER, H., NAIM, H.Y., DEGLON, N., and LUNDSTROM, K. (2001). Gene transfer into neurons from hippocampal slices: Comparison of recombinant Semliki Forest virus, adenovirus, adeno-associated virus, lentivirus, and measles virus. Mol. Cell. Neurosci. 17, 855-871.
27. ESLAMBOLI, A., CUMMINGS, R.M., RIDLEY, R.M., BAKER, H.F., MUZYCZKA, N., BURGER, C., MANDEL, R.J., KIRIK, D., and ANNETT, L.E. (2003). Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp. Neurol. 184, 536-548.
28. ESLAMBOLI, A., GEORGIEVSKA, B., RIDLEY, R.M., BAKER, H.F., MUZYCZKA, N., BURGER, C., MANDEL, R.J., ANNETT, L., and KIRIK, D. (2005). Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J. Neurosci. 25, 769-777.
29. FAN, D.S., OGAWA, M., FUJIMOTO, K.I., IKEGUCHI, K., OGASAWARA, Y., URABE, M., NISHIZAWA, M., NAKANO, I., YOSHIDA, M., NAGATSU, I., ICHINOSE, H., NAGATSU, T., KURTZMAN, G.J., and OZAWA, K. (1998). Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors. Hum. Gene Ther. 9, 2527-2535.
30. FITZSIMONS, H.L., MCKENZIE, J.M., and DURING, M.J. (2001). Insulators coupled to a minimal bidirectional let cassette for tight regulation of rAAV-mediated gene transfer in the mammalian brain. Gene Ther. 8, 1675-1681.
31. FLANNERY, J.G., ZOLOTUKHIN, S., VAQUERO, M.I., LAVAIL, M.M., MUZYCZKA, N., and HAUSWIRTH, W.W. (1997). Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc. Natl. Acad. Sci. U.S.A. 94, 6916-6921.
32. FLEMING, J., GINN, S.L., WEINBERGER, R.P., TRAHAIR, T.N., SMYTHE, J.A., and ALEXANDER, I.E. (2001). Adeno-associated virus and lentivirus vectors mediate efficient and sustained transduction of cultured mouse and human dorsal root ganglia sensory neurons. Hum. Gene Ther. 12, 77-86.
33. FLOTTE, T.R., AFIONE, S.A., SOLOW, R., DRUMM, M.L., MARKAKIS, D., GUGGINO, W.B., ZEITLIN, P.L., and CARTER, B.J. (1993). Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter. J. Biol. Chem. 268, 3781-3790.
34. FOLLIOT, S., BRIOT, D., CONRATH, H., PROVOST, N., CHEREL, Y., MOULLIER, P., and ROLLING, F. (2003). Sustained tetracycline-regulated transgene expression in vivo in rat retinal ganglion cells using a single type 2 adeno-associated viral vector. J. Gene Med. 5, 493-501.
35. FREESE, A., KAPLITT, M.G., O'CONNOR, W.M., ABBEY, M., LANGER, D., LEONE, P., O'CONNOR, M.J., and DURING, M.J. (1997). Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: Implications for a gene therapy approach to epilepsy. Epilepsia 38, 759-766.
36. FU, H., SAMULSKI, R.J., MCCOWN, T.J., PICORNELL, Y.J., FLETCHER, D., and MUENZER, J. (2002). Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol. Ther. 5, 42-49.
37. FU, H., MUENZER, J., SAMULSKI, R.J., BREESE, G., SIFFORD, J., ZENG, X., and MCCARTY, D.M. (2003). Self-complementary adeno-associated virus serotype 2 vector: Global distribution and broad dispersion of AAV-mediated transgene expression in mouse brain. Mol. Ther. 8, 911-917.
38. PURLER, S., PATERNA, J.C., WEIBEL, M., and BUELER, H. (2001). Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons. Gene Ther. 8, 864-873.
39. GAFNI, Y., PELLED, G., ZILBERMAN, Y., TURGEMAN, G., APPARAILLY, F., YOTVAT, H., GALUN, E., GAZIT, Z., JORGENSEN, C., and GAZIT, D. (2004). Gene therapy platform for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol. Ther. 9, 587-595.
40. GAO, G., ALVIRA, M.R., SOMANATHAN, S., LU, Y., VANDENBERGHE, L.H., RUX, J.J., CALCEDO, R., SANMIGUEL, J., ABBAS, Z., and WILSON, J.M. (2003). Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. U.S.A. 100, 6081-6086.
41. GAO, G.P., ALVIRA, M.R., WANG, L., CALCEDO, R., JOHNSTON, J., and WILSON, J.M. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 11854-11859.
42. GLATZEL, M., FLECHSIG, E., NAVARRO, B., KLEIN, M.A., PATERNA, J.C., BUELER, H., and AGUZZI, A. (2000). Adenoviral and adeno-associated viral transfer of genes to the peripheral nervous system. Proc. Natl. Acad. Sci. U.S.A. 97, 442-447.
43. GOSSEN, M., and BUJARD, H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U.S.A. 89, 5547-5551.
44. GOSSEN, M., FREUNDLIEB, S., BENDER, G., MULLER, G., HILLEN, W., and BUJARD, H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science 268, 1766-1769.
45. GRIMM, D., and KAY, M.A. (2003). From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy. Curr. Gene Ther. 3, 281-304.
46. GUNDERSEN, H.J., and JENSEN, E.B. (1987). The efficiency of systematic sampling in stereology and its prediction. J. Microsc. 147, 229-263.
47. HABERMAN, R.P., and MCCOWN, T.J. (2002). Regulation of gene expression in adeno-associated virus vectors in the brain. Methods 28, 219-226.
48. HABERMAN, R.P., MCCOWN, T.J., and SAMULSKI, R.J. (2000). Novel transcriptional regulatory signals in the adeno-associated virus terminal repeat A/D junction element. J. Virol. 74, 8732-8739.
49. HABERMAN, R., CRISWELL, H., SNOWDY, S., MING, Z., BREESE, G., SAMULSKI, R., and MCCOWN, T. (2002). Therapeutic liabilities of in vivo viral vector tropism: Adeno-associated virus vectors, NM-DAR1 antisense, and focal seizure sensitivity. Mol. Ther. 6, 495-500.
50. HABERMAN, R.P., SAMULSKI, R.J., and MCCOWN, T.J. (2003). Attenuation of seizures and neuronal death by adeno-associated virus vector galanin expression and secretion. Nat. Med. 9, 1076-1080.
51. HADACZEK, P., MIREK, H., BRINGAS, J., CUNNINGHAM, J., and BANKIEWICZ, K. (2004). Basic fibroblast growth factor enhances transduction, distribution, and axonal transport of adeno-associated virus type 2 vector in rat brain. Hum. Gene Ther. 15, 469-479.
52. HALBERT, C.L., ALLEN, J.M., and MILLER, A.D. (2001). Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared with that of AAV2 vectors. J. Virol. 75, 6615-6624.
53. HAUCK, B., ZHAO, W., HIGH, K., and XIAO, W. (2004). Intracellular viral processing, not single-stranded DNA accumulation, is crucial for recombinant adeno-associated virus transduction. J. Virol. 78, 13678-13686.
54. IDENO, J., MIZUKAMI, H., HONDA, K., OKADA, T., HANAZONO, Y., KUME, A., SAITO, T., ISHIBASHI, S., and OZAWA, K. (2003). Persistent phenotypic correction of central diabetes insipidus using adeno-associated virus vector expressing arginine-vasopressin in Brattleboro rats. Mol. Ther. 8, 895-902.
55. JIANG, L., RAMPALLI, S., GEORGE, D., PRESS, C., BREMER, E.G., O'GORMAN, M.R., and BOHN, M.C. (2004). Tight regulation from a single tet-off rAAV vector as demonstrated by flow cytometry and quantitative, real-time PCR. Gene Ther. 11, 1057-1067.
56. JOHNSTON, J., TAZELAAR, J., RIVERA, V.M., CLACKSON, T., GAO, G.P., and WILSON, J.M. (2003). Regulated expression of erythropoietin from an AAV vector safely improves the anemia of β-thalassemia in a mouse model. Mol. Ther. 7, 493-497.
57. KALUDOV, N., HANDELMAN, B., and CHIORINI, J.A. (2002). Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum. Gene Ther. 13, 1235-1243.
58. KAPLITT, M.G., LEONE, P., SAMULSKI, R.J., XIAO, X., PFAFF, D.W., O'MALLEY, K.L., and DURING, M.J. (1994). Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8, 148-154.
59. KASPAR, B.K., ERICKSON, D., SCHAFFER, D., HINH, L., GAGE, F.H., and PETERSON, D.A. (2002a). Targeted retrograde gene delivery for neuronal protection. Mol. Ther. 5, 50-56.
60. KASPAR, B.K., VISSEL, B., BENGOECHEA, T., CRONE, S., RANDOLPH-MOORE, L., MULLER, R., BRANDON, E.P., SCHAFFER, D., VERMA, I.M., LEE, K.F., HEINEMANN, S.F., and GAGE, F.H. (2002b). Adeno-associated virus effectively mediates conditional gene modification in the brain. Proc. Natl. Acad. Sci. U.S.A. 99, 2320-2325.
61. KIRIK, D., ROSENBLAD, C., and BJORKLUND, A. (1998). Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152, 259-277.
62. KIRIK, D., GEORGIEVSKA, B., BURGER, C., WINKLER, C., MUZYCZKA, N., MANDEL, R.J., and BJORKLUND, A. (2002). Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc. Natl. Acad. Sci. U.S.A. 99, 4708-4713.
63. KLEIN, R.L., MEYER, E.M., PEEL, A.L., ZOLOTUKHIN, S., MEYERS, C., MUZYCZKA, N., and KING, M.A. (1998). Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp. Neurol. 150, 183-194.
64. KLEIN, R.L., HIRKO, A.C., MEYERS, C.A., GRIMES, J.R., MUZYCZKA, N., and MEYER, E.M. (2000). NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats. Brain Res. 875, 144-151.
65. KLEIN, R.L., HAMBY, M.E., SONNTAG, C.F., MILLARD, W.J., KING, M.A., and MEYER, E.M. (2002). Measurements of vector-derived neurotrophic factor and green fluorescent protein levels in the brain. Methods 28, 286-292.
66. KLUGMANN, M., WYMOND SYMES, C., LEICHTLEIN, C.B., KLAUSSNER, B.K., DUNNING, J., FONG, D., YOUNG, D., and DURING, M.J. (2005). AAV-mediated hippocampal expression of short and long Homer 1 proteins differentially affect cognition and seizure activity in adult rats. Mol. Cell. Neurosci. 28, 347-360.
67. KRONENBERG, S., KLEINSCHMIDT, J.A., and BOTTCHER, B. (2001). Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2, 997-1002.
68. LANDGRAF, R., FRANK, E., ALDAG, J.M., NEUMANN, I.D., SHARER, C.A., REN, X., TERWILLIGER, E.F., NIWA, M., WIGGER, A., and YOUNG, L.J. (2003). Viral vector-mediated gene transfer of the vole V1a vasopressin receptor in the rat septum: Improved social discrimination and active social behaviour. Eur. J. Neurosci. 18, 403-411.
69. LANG, A.E., GILL, S., BROOKS, D., BRODSKY, M.A., BURCHIEL, K., COFFEY, R.J., DALVI, A., DHAWAN, V., ELIAS, W.J., HEYWOOD, P., HOTTON, G., HUTCHINSON. M., KELLY, P., LAWS, E.R., LOZANO, A., MATCHAM, J., MORO, E., NUTT, J., PATEL, N.K., PENN, R., SCOTT, B., STACY, M., STOESSL, A.J., TRAUB, M., TURNER, D., and WOOTEN, G.F. (2004). Multicenter, double-blind, randomized, placebo-controlled, parallel group trial of liatermin (rmetHuGDNF) administered by bilateral intraputaminal (IPu) infusion to subjects with idiopathic Parkinson's disease. In 129th Annual Meeting of the American Neurological Association, Toronto, Canada (American Neurological Association, Minneapolis, MN).
70. LEFF, S.E., SPRATT, S.K., SNYDER, R.O., and MANDEL, R.J. (1999). Long-term restoration of striatal L-aromatic amino acid decarboxylase activity using recombinant adeno-associated viral vector gene transfer in a rodent model of Parkinson's disease. Neuroscience 92, 185-196.
71. LIN, E.J., RICHICHI, C., YOUNG, D., BAER, K., VEZZANI, A., and DURING, M.J. (2003). Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur. J. Neurosci. 18, 2087-2092.
72. LO, W.D., QU, G., SFERRA, T.J., CLARK, R., CHEN, R., and JOHNSON, P.R. (1999). Adeno-associated virus-mediated gene transfer to the brain: Duration and modulation of expression. Hum. Gene Ther. 10, 201-213.
73. LOEB, J.E., CORDIER, W.S., HARRIS, M.E., WEITZMAN, M.D., and HOPE, T.J. (1999). Enhanced expression of transgenes from adeno-associated virus vectors with the woodchuck hepatitis virus posttranscriptional regulatory element: Implications for gene therapy. Hum. Gene Ther. 10, 2295-2305.
74. LOUBOUTIN, J.P., WANG, L., and WILSON, J.M. (2004). Gene transfer into skeletal muscle using novel AAV serotypes. J. Gene Med. 7, 442-451.
75. LOWENSTEIN, P.R. (2004). Input virion proteins: Cryptic targets of antivector immune responses in preimmunized subjects. Mol. Ther. 9, 771-774.
76. LOWENSTEIN, P.R., and CASTRO, M.G. (2003). Inflammation and adaptive immune responses to adenoviral vectors injected into the brain: Peculiarities, mechanisms, and consequences. Gene Ther. 10, 946-954.
77. MANDEL, R.J., and BURGER, C. (2004). Clinical trials in neurological disorders using AAV vectors: Promises and challenges. Curr. Opin. Mol. Ther. 6, 482-490.
78. MANDEL, R.J., SPRATT, S.K., SNYDER, R.O., and LEFF, S.E. (1997). Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc. Natl. Acad. Sci. U.S.A. 94, 14083-14088.
79. MANDEL, R.J., RENDAHL, K.G., SPRATT, S.K., SNYDER, R.O., COHEN, L.K., and LEFF, S.E. (1998). Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase 1 in a rat model of Parkinson's disease. J. Neurosci. 18, 4271-4284.
80. MANDEL, R.J., GAGE, F.H., CLEVENGER, D.G., SPRATT, S.K., SNYDER, R.O., and LEFF, S.E. (1999a). Nerve growth factor expressed in the medial septum following in vivo gene delivery using a recombinant adeno-associated viral vector protects cholinergic neurons from fimbria-fornix lesion-induced degeneration. Exp. Neurol. 155, 59-64.
81. MANDEL, R.J., RENDAHL, K.G., SNYDER, R.O., and LEFF, S.E. (1999b). Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp. Neurol. 159, 47-64.
82. MARTINOV, V.N., SEFLAND, I., WALAAS, S.I., LOMO, T., NJA, A., and HOOVER, F. (2002). Targeting functional subtypes of spinal motoneurons and skeletal muscle fibers in vivo by intramuscular injection of adenoviral and adeno-associated viral vectors. Anat. Embryol. (Berl.) 205, 215-221.
83. MASTAKOV, M.Y., BAER, K., XU, R., FITZSIMONS, H., and DURING, M.J. (2001). Combined injection of rAAV with mannitol enhances gene expression in the rat brain. Mol. Ther. 3, 225-232.
84. MASTAKOV, M.Y., BAER, K., KOTIN, R.M., and DURING, M.J. (2002). Recombinant adeno-associated virus serotypes 2- and 5-mediated gene transfer in the mammalian brain: Quantitative analysis of heparin co-infusion. Mol. Ther. 5, 371-380.
85. MATALON, R., SURENDRAN, S., RADY, P.L., QUAST, M.J., CAMPBELL, G.A., MATALON, K.M., TYRING, S.K., WEI, J., PEDEN, C.S., EZELL, E.L., MUZYCZKA, N., and MANDEL, R.J. (2003). Adeno-associated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for Canavan disease. Mol. Ther. 7, 580-587.
86. MCCOWN, T.J., XIAO, X., LI, J., BREESE, G.R., and SAMULSKI, R.J. (1996). Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713, 99-107.
87. MURAMATSU, S., FUJIMOTO, K., IKEGUCHI, K., SHIZUMA, N., KAWASAKI, K., ONO, F., SHEN, Y., WANG, L., MIZUKAMI, H., KUME, A., MATSUMURA, M., NAGATSU, I., URANO, F., ICHINOSE, H., NAGATSU, T., TERAO, K., NAKANO, I., and OZAWA, K. (2002). Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 13, 345-354.
88. MUZYCZKA, N., and BERNS, K.I. (2001). Parvoviridae: The viruses and their replication. In Fields Virology. D.M. Knipe and Howley, P.M., eds. (Lippincott, Williams & Wilkins, New York) pp. 2327-2360.
89. NARFSTROM, K., KATZ, M.L., BRAGADOTTIR, R., SEELIGER, M., BOULANGER, A., REDMOND, T.M., CARD, L., LAI, C.M., and RAKOCZY, P.E. (2003). Functional and structural recovery of the retina after gene therapy in the RPE65 null mutation dog. Invest. Ophthalmol. Vis. Sci. 44, 1663-1672.
90. NGUYEN, J.B., SANCHEZ-PERNAUTE, R., CUNNINGHAM, J., and BANKIEWICZ, K.S. (2001). Convection-enhanced delivery of AAV-2 combined with heparin increases TK gene transfer in the rat brain. Neuroreport 12, 1961-1964.
91. NIWA, H., YAMAMURA, K., and MIYAZAKI, J. (1991). Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108, 193-199.
92. NO, D., YAO, T.P., and EVANS, R.M. (1996). Ecdysone-inducible gene expression in mammalian cells and transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 93, 3346-3351.
93. OPIE, S.R., WARRINGTON JR, K.H., JR., AGBANDJE-MCKENNA, M., ZOLOTUKHIN, S., and MUZYCZKA, N. (2003). Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J. Virol. 77, 6995-7006.
94. OWEN, R.T., MANDEL, R.J., AMMINI, C.V., CONLON, T.J., KERR, D.S., STACPOOLE, P.W., and FLOTTE, T.R. (2002). Gene therapy for pyruvate dehydrogenase E1α deficiency using recombinant adeno-associated virus 2 (rAAV2) vectors. Mol. Ther. 6, 394-399.
95. PASSINI, M.A., LEE, E.B., HEUER, G.G., and WOLFE, J.H. (2002). Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J. Neurosci. 22, 6437-6446.
96. PASSINI, M.A., WATSON, D.J., VITE, C.H., LANDSBURG, D.J., FEIGENBAUM, A.L., and WOLFE, J.H. (2003). Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the Brains of β-glucuronidase-deficient mice. J. Virol. 77, 7034-7040.
97. PATERNA, J.C., MOCCETTI, T., MURA, A., FELDON, J., and BUELER, H. (2000). Influence of promoter and WHV post-transcriptional regulatory element on AAV-mediated transgene expression in the rat brain. Gene Ther. 7, 1304-1311.
98. PATERNA, J.C., FELDON, J., and BUELER, H. (2004). Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J. Virol. 78, 6808-6817.
99. PAXINOS, G., and WATSON, C. (1997). The Rat Brain in Stereotaxic Coordinates. (Academic Press, Orlando, FL).
100. PEDEN, C.S., BURGER, C., MUZYCZKA, N., and MANDEL, R.J. (2004). Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAVS-mediated, gene transfer in the brain. J. Virol. 78, 6344-6359.
101. PEEL, A.L., ZOLOTUKHIN, S., SCHRIMSHER, G.W., MUZYCZKA, N., and REIER, P.J. (1997). Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther. 4, 16-24.
102. PROSCH, S., STEIN, J., STAAK, K., LIEBENTHAL, C., VOLK, H.D., and KRUGER, D.H. (1996). Inactivation of the very strong HCMV immediate early promoter by DNA CpG methylation in vitro. Biol. Chem. Hoppe Seyler 377, 195-201.
103. QING, K., MAH, C., HANSEN, J., ZHOU, S., DWARKI, V., and SRIVASTAVA, A. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5, 71-77.
104. RICHICHI, C., LIN, E.J., STEFANIN, D., COLELLA, D., RAVIZZA, T., GRIGNASCHI, G., VEGLIANESE, P., SPERK, G., DURING, M.J., and VEZZANI, A. (2004). Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus. J. Neurosci. 24, 3051-3059.
105. RIVERA, V.M., CLACKSON, T., NATESAN, S., POLLOCK, R., AMARA, J.F., KEENAN, T., MAGARI, S.R., PHILLIPS, T., COURAGE, N.L., CERASOLI, F., Jr., HOLT, D.A., and GILMAN, M. (1996). A humanized system for pharmacologic control of gene expression. Nat. Med. 2, 1028-1032.
106. RIVERA, V.M., YE, X., COURAGE, N.L., SACHAR, J., CERASOLI, F., Jr., WILSON, J.M., and GILMAN, M. (1999). Long-term regulated expression of growth hormone in mice after intramuscular gene transfer. Proc. Natl. Acad. Sci. U.S.A. 96, 8657-8662.
107. RUITENBERG, M.J., BLITS, B., DIJKHUIZEN, P.A., TE BEEK, E.T., BAKKER, A., VAN HEERIKHUIZE, J.J., POOL, C.W., HERMENS, W.T., BOER, G.J., and VERHAAGEN, J. (2004). Adeno-associated viral vector-mediated gene transfer of brain-derived neurotrophic factor reverses atrophy of rubrospinal neurons following both acute and chronic spinal cord injury. Neurobiol. Dis. 15, 394-406.
108. SAMAKOGLU, S., BOHL, D., and HEARD, J.M. (2002). Mechanisms leading to sustained reversion of β-thalassemia in mice by doxycycline-controlled Epo delivery from muscles. Mol. Ther. 6, 793-803.
109. SANFTNER, L.M., SUZUKI, B.M., DOROUDCHI, M.M., FENG, L., MCCLELLAND, A., FORSAYETH, J.R., and CUNNINGHAM, J. (2004). Striatal delivery of rAAV-hAADC to rats with preexisting immunity to AAV. Mol. Ther. 9, 403-409.
110. SCAMMELL, T.E., ARRIGONI, E., THOMPSON, M.A., RONAN, P.J., SAPER, C.B., and GREENE, R.W. (2003). Focal deletion of the adenosine A1 receptor in adult mice using an adeno-associated viral vector. J. Neurosci. 23, 5762-5770.
111. SHEN, Y., MURAMATSU, S.I., IKEGUCHI, K., FUJIMOTO, K.I., FAN, D.S., OGAWA, M., MIZUKAMI, H., URABE, M., KUME, A., NAGATSU, I., URANO, F., SUZUKI, T., ICHINOSE, H., NAGATSU, T., MONAHAN, J., NAKANO, I., and OZAWA, K. (2000). Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase 1 for gene therapy of Parkinson's disease. Hum. Gene Ther. 11, 1509-1519.
112. SHIMAZAKI, K., URABE, M., MONAHAN, J., OZAWA, K., and KAWAI, N. (2000). Adeno-associated virus vector-mediated bcl-2 gene transfer into post-ischemic gerbil brain in vivo: Prospects for gene therapy of ischemia-induced neuronal death. Gene Ther. 7, 1244-1249.
113. SMITH, R.H., DING, C., and KOTIN, R.M. (2003). Serum-free production and column purification of adeno-associated virus type 5. J. Virol. Methods 114, 115-124.
114. SUMMERFORD, C., and SAMULSKI, R.J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445.
115. 5 integrin: A co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82.
116. SZCZYPKA, M.S., MANDEL, R.J., DONAHUE, B.A., SNYDER, R.O., LEFF, S.E., and PALMITER, R.D. (1999). Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice. Neuron 22, 167-178.
117. TENENBAUM, L., JURYSTA, F., STATHOPOULOS, A., PUSCHBAN, Z., MELAS, C., HERMENS, W.T., VERHAAGEN, J., PICHON, B., VELU, T., and LEVIVIER, M. (2000). Tropism of AAV-2 vectors for neurons of the globus pallidus. Neuroreport 11, 2277-2283.
118. THOMAS, C.E., STORM, T.A., HUANG, Z., and KAY, M.A. (2004). Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J. Virol. 78, 3110-3122.
119. URLINGER, S., BARON, U., THELLMANN, M., HASAN, M.T., BUJARD, H., and HILLEN, W. (2000). Exploring the sequence space for tetracycline-dependent transcriptional activators: Novel mutations yield expanded range and sensitivity. Proc. Natl. Acad. Sci. U.S.A. 97, 7963-7968.
120. VITE, C.H., PASSINI, M.A., HASKINS, M.E., and WOLFE, J.H. (2003). Adeno-associated virus vector-mediated transduction in the cat brain. Gene Ther. 10, 1874-1881.
121. WALTERS, R.W., YI, S.M., KESHAVJEE, S., BROWN, K.E., WELSH, M.J., CHIORINI, J.A., and ZABNER, J. (2001). Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J. Biol. Chem. 276, 20610-20616.
122. WANG, A.Y., PENG, P.D., EHRHARDT, A., STORM, T.A., and KAY, M.A. (2004). Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Hum. Gene Ther. 15, 405-413.
123. WANG, C., WANG, C.M., CLARK, K.R., and SFERRA, T.J. (2003). Recombinant AAV serotype 1 transduction efficiency and tropism in the murine brain. Gene Ther. 10, 1528-1534.
124. WANG, L., MURAMATSU, S., LU, Y., IKEGUCHI, K., FUJIMOTO, K., OKADA, T., MIZUKAMI, H., HANAZONO, Y., KUME, A., URANO, F., ICHINOSE, H., NAGATSU, T., NAKANO, I., and OZAWA, K. (2002). Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther. 9, 381-389.
125. WANG, L., CALCEDO, R., NICHOLS, T.C., BELLINGER, D.A., DILLOW, A., VERMA, I.M., and WILSON, J.M. (2005). Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8 mediated, liver-directed gene therapy. Blood 105, 3079-3086.
126. WANG, Y., O'MALLEY, B.W., JR., TSAI, S.Y., and O'MALLEY, B.W. (1994). A regulatory system for use in gene transfer. Proc. Natl. Acad. Sci. U.S.A. 91, 8180-8184.
127. WARRINGTON, K.H., Jr., GORBATYUK, O.S., HARRISON, J.K., OPIE, S.R., ZOLOTUKHIN, S., and MUZYCZKA, N. (2004). Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J. Virol. 78, 6595-6609.
128. WEBER, M., RABINOWITZ, J., PROVOST, N., CONRATH, H., FOLLIOT, S., BRIOT, D., CHEREL, Y., CHENUAUD, P., SAMULSKI, J., MOULLIER, P., and ROLLING, F. (2003). Recombinant adeno-associated virus serotype 4 mediates unique and exclusive long-term transduction of retinal pigmented epithelium in rat, dog, and nonhuman primate after subretinal delivery. Mol. Ther. 7, 774-781.
129. WEST, M.J., SLOMIANKA, L., and GUNDERSEN, H.J. (1991). Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 231, 482-497.
130. WU, P., XIAO, W., CONLON, T., HUGHES, J., AGBANDJE-MCKENNA, M., FERKOL, T., FLOTTE, T., and MUZYCZKA, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647.
131. XIE, Q., BU, W., BHATIA, S., HARE, J., SOMASUNDARAM, T., AZZI, A., and CHAPMAN, M.S. (2002). The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc. Natl. Acad. Sci. U.S.A. 99, 10405-10410.
132. XU, Y., GU, Y., WU, P., LI, G.W., and HUANG, L.Y. (2003). Efficiencies of transgene expression in nociceptive neurons through different routes of delivery of adeno-associated viral vectors. Hum. Gene Ther. 14, 897-906.
133. YANG, G.S., SCHMIDT, M., YAN, Z., LINDBLOOM, J.D., HARDING, T.C., DONAHUE, B.A., ENGELHARDT, J.F., KOTIN, R., and DAVIDSON, B.L. (2002). Virus-mediated transduction of murine retina with adeno-associated virus: Effects of viral capsid and genome size. J. Virol. 76, 7651-7660.
134. YE, X., RIVERA, V.M., ZOLTICK, P., CERASOLI, F., Jr., SCHNELL, M.A., GAO, G., HUGHES, J.V., GILMAN, M., and WILSON, J.M. (1999). Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer. Science 283, 88-91.
135. ZOLOTUKHIN, S., POTTER, M., ZOLOTUKHIN, I., SAKAI, Y., LOILER, S., FRAITES, T.J., Jr., CHIODO, V.A., PHILLIPSBERG, T., MUZYCZKA, N., HAUSWIRTH, W.W., FLOTTE, T.R., BYRNE, B.J., and SNYDER, R.O. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28, 158-167.